Artificial intelligence (AI) has burst into the healthcare field, revolutionizing the early detection of breast cancer, one of the most important challenges in modern medicine. The power of AI systems, especially those developed by companies like Google, is transforming the screening and diagnosis of this disease thanks to their accuracy, speed, and ability to process large volumes of data.
Currently, breast cancer is one of the most common types of cancer worldwide, with the vast majority of cases affecting women, according to data from the World Health Organization (WHO). Early detection is key to increasing survival rates and reducing invasive treatments. In this context, artificial intelligence applied to medicine is positioned as a fundamental support tool for healthcare professionals.
How does Google's artificial intelligence work in breast cancer detection?
Google's AI has been trained using deep neural networks (deep learning) with large databases containing medical images, primarily mammograms. This training allows identify subtle patterns or micro lesions in images that may even go unnoticed by the human eye, improving the sensitivity and specificity of the diagnosis.
In the most relevant studies, more than 76.000 anonymous mammograms of women from the UK and 15.000 from the US, as well as independent data sets to evaluate the algorithm's performance. The results showed a significant reduction in false negatives and positives, which helps minimize misdiagnoses and the anxiety and costs associated with unnecessary tests and treatments.
- Reduction of false negatives: 9,4% in women in the United States and 2,7% in the United Kingdom, meaning the AI identified cases that doctors might miss.
- Reduction of false positives: 5,7% in the United States and 1,2% in the United Kingdom, streamlining clinical decision-making and avoiding unnecessary interventions.
In cross-country tests, when the AI was trained on data from one country and tested on data from another—for example, trained on British mammograms and tested on American ones— The reduction in false negatives reached 8,1% and that of false positives reached 3,5%.These results demonstrate the robustness and generalizability of Google's model.
Advantages of artificial intelligence over traditional diagnosis
Conventional mammography, despite being the standard method for breast cancer screening, has inherent limitations: breast density can mask tumors, there is variability between radiologists, and an estimated diagnostic error rate of up to 20%. AI is presented as an ally to overcome these barriers, providing numerous benefits:
- Processing of large volumes of data: Analyze thousands of images in a matter of minutes, detecting imperceptible patterns.
- Reducing the workload of radiologists: It allows efforts to be focused on complex cases and double readings to be performed without increasing the pressure on care.
- Diagnostic agility: The wait time for results can go from two weeks to just three days—a crucial difference in patient anxiety and prognosis.
- Greater accuracy and fairness: It reduces human variability and contributes to more consistent diagnoses, regardless of the medical center or professional performing the test.
Some systems, such as the LYNA (Lymph Node Assistant) Google's AI tools have been shown to locate metastases almost invisible to the human eye, speeding up diagnoses and the start of treatment. And internationally, AI tools like MIA, developed by Kheiron Medical Technologies and Microsoft in conjunction with the University of Aberdeen, have increased case detection by 13% compared to conventional methods and could reduce caseload by 30%.
Current limitations and future challenges of AI in cancer detection
While artificial intelligence is reaching levels of accuracy superior to those of many human experts, still has significant limitations:
- Limited access to contextual information: AI typically analyzes only the most recent image, without access to a complete medical history or previous mammograms, which could limit the detection of subtle changes over time.
- Lack of real-time learning: For regulatory reasons, some clinical trials disable machine learning during the validation phase to avoid bias or uncontrolled errors. Each update requires human oversight and further validation.
- It does not replace human assessment: Although it reduces errors, it should always be used as a complement to medical opinion, never as a complete substitute. There are cases in which radiologists detect anomalies that AI fails to identify.
- Privacy and anonymization: Protecting personal data—for example, by removing identifiers before uploading mammograms to the cloud for AI analysis—is critical to ensuring patient confidentiality.
Therefore, the international consensus, supported by associations such as the College of Radiologists of the United Kingdom, advocates Collaboration between artificial intelligence and radiologists: The radiologist using validated AI will increasingly become a key and robust figure in clinical care.
Global applications and clinical validation of AI in breast cancer detection
The use of artificial intelligence It has already been approved by entities such as the FDA in the US, the European Medicines Agency, and ANMAT in Argentina.More than 20 institutions in XNUMX countries currently use it for interpreting mammograms, ultrasounds, and MRIs.
In trials conducted in British and other European hospitals, tools such as MIA have been able to identify tumors smaller than 6 millimeters that were missed in human re-readings, demonstrating AI's ability to detect lesions in early stages. In larger international studies, a diagnostic sensitivity of up to 98% and a reduction of up to 30% in unnecessary biopsies of benign lesions, optimizing resources and minimizing the emotional and physical impact on patients.
Furthermore, AI has proven its usefulness even in contexts of high demand and work stress, helping to reduce radiologists' fatigue and improving diagnostic quality. Its integration into clinical workflows allows, for example, an automatic initial assessment of malignancy risk and prioritization of the most urgent cases.
Success stories and scientific recognition
- In the UK, AI identified 11 cases of breast cancer that had gone undetected by doctors, enabling less invasive treatments and improving the survival rate for tumors smaller than 15 mm, which can exceed 90%.
- In Sweden, recent trials showed a 20% improvement in tumor detection when mammograms were evaluated by AI and a radiologist compared to double-checking by humans.
Furthermore, the scientific community has recognized the disruptive impact of AI with awards as important as the Nobel Prize in Physics to Geoffrey Hinton and John Hopfield for his contributions to neural networks—a fundamental technological basis for the development of current algorithms for medical imaging—and the Nobel Prize in Chemistry to Google DeepMind scientists for AlphaFold, a program that predicts protein structures and opens new horizons in the diagnosis and treatment of cancer.
The future of artificial intelligence in breast cancer: opportunities and challenges
The path to the full implementation of artificial intelligence in breast cancer detection involves overcoming regulatory, technical, and ethical challenges. For widespread adoption, it is essential to:
- Standardize diagnostic data and systems: Algorithms must be validated in diverse populations and trained with images of patients of different ethnicities and characteristics.
- Protect privacy: Data anonymization is a sine qua non for trust and adoption in the healthcare sector.
- Train professionals: Ongoing training is required as the radiologist's role evolves to interpret results and make clinical decisions in collaboration with AI.
- Investigate the long-term impact: Prospective studies (such as those conducted in Great Britain and Hungary) are underway to assess the real-world impact on mortality, cost reduction, and improved patient experience.
Upgrades to AI systems are expected to enable continuous learning in real-world clinical settings, improving the detection of difficult cases and adapting to changes in imaging technologies and epidemiological patterns.
Gender perspective and technological equity
Adriana Noreña, Google's vice president for Latin America, emphasizes the importance of women actively participate in the development of these technologies, thus ensuring more equitable solutions tailored to the specific needs of women. Integrating the female perspective from the earliest stages of AI design and implementation will be crucial to ensuring the effectiveness, usefulness, and ethical nature of the tools created.
The medical community and technology companies like Google are committed to continuing to advance the democratization of access to accurate, rapid, and personalized healthcare. AI is not only an ally in breast cancer detection, but also in prevention, monitoring, and, eventually, personalized treatment.
The integration of artificial intelligence into breast cancer detection represents one of the greatest milestones in modern medicine. Clinical trials and real-life testimonials confirm that AI, when used as a complement to traditional medical evaluation, allows for more accurate, faster and more equitable diagnosesAs the technology matures and ethical and privacy standards become more established, AI from Google and other leading companies will continue to save lives and transform the healthcare paradigm.
